Occurrence of endoscopic ulcers in patients receiving misoprostol (miso), standard or double dose H2 receptor antagonist (st-H2RA or dd-H2RA), or proton pump inhibitor (PPI) treatments for ≥3 months compared with placebo (pl) during non-steroidal anti-inflammatory drug (NSAID) use*
| Comparisons | Ulcer | Weighted event rates | RRR (95% CI) | NNT (CI)† |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article using a fixed effects model. | ||||
| †Calculated for endoscopic, not clinical, outcomes. | ||||
| Miso v pl | Gastric | 2.5% v 12.9% | 75% (67 to 82) | 10 (9 to 12) |
| Duodenal | 2.6% v 6.1% | 54% (34 to 69) | 29 (20 to 53) | |
| st-H2RA v pl | Duodenal | 11.5% v 25.9% | 64% (26 to 82) | 29 (17 to 84) |
| dd-H2RA v pl | Gastric | 2.0% v 5.5% | 56% (26 to 74) | 7 (5 to 17) |
| Duodenal | 3.4% v 13.6% | 74% (35 to 89) | 10 (7 to 25) | |
| PPI v pl | Gastric | 6.6% v 19.6% | 61% (45 to 73) | 8 (6 to 13) |
| Duodenal | 1.7% v 10.3% | 81% (60 to 91) | 12 (9 to 20) | |
